A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
Latest Information Update: 28 Aug 2023
At a glance
- Drugs RAAV2tYF-PR.1-hCNGA3 (Primary)
- Indications Colour vision defects
- Focus Adverse reactions
- Sponsors Applied Genetic Technologies Corporation; Beacon Therapeutics
- 20 Jul 2022 Planned End Date changed from 1 Sep 2025 to 1 Aug 2026.
- 20 Jul 2022 Planned primary completion date changed from 1 Sep 2021 to 1 Aug 2022.
- 20 Jul 2022 Status changed from recruiting to active, no longer recruiting.